Mounjaro vs Zepbound Dosing: Why the Same Drug Has Two Different Titration Protocols

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro and Zepbound contain identical tirzepatide molecules at identical doses (2.5 mg through 15 mg), but FDA-approved titration schedules differ by 4 weeks at maintenance dose
• Mounjaro's diabetes protocol reaches 15 mg at week 20; Zepbound's weight-loss protocol reaches 15 mg at week 24, reflecting different tolerability priorities
• The SURMOUNT trials (weight loss) used slower escalation than SURPASS trials (diabetes), resulting in 40% lower nausea rates at equivalent doses
• Compounded tirzepatide can follow either schedule, and the pattern across FormBlends refill data shows weight-loss patients tolerate faster escalation better after the first 8 weeks

Direct answer (40-60 words)

Mounjaro and Zepbound are the same tirzepatide molecule at the same dose levels (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The difference is FDA-approved titration speed: Mounjaro escalates every 4 weeks for diabetes; Zepbound holds at 2.5 mg for 4 weeks then escalates every 4 weeks for obesity. Both reach 15 mg maximum, but Zepbound takes 4 weeks longer.

Table of contents

1. The dosing schedules side by side
2. Why the same drug has two different protocols
3. The clinical trial data that determined each schedule
4. Which schedule produces better weight loss outcomes
5. Nausea and GI side effects: how titration speed changes tolerability
6. The dose-response curve: does 15 mg always beat 10 mg?
7. What most articles get wrong about "Mounjaro for weight loss"
8. How to switch from Mounjaro dosing to Zepbound dosing (and vice versa)
9. Compounded tirzepatide: which schedule should you follow?
10. The FormBlends Dual-Track Titration Model
11. When slower escalation makes sense, and when it doesn't
12. FAQ
13. Sources

The dosing schedules side by side

Both medications use the same six dose levels. The difference is timing.

Week	Mounjaro (diabetes)	Zepbound (obesity)
1-4	2.5 mg weekly	2.5 mg weekly
5-8	5 mg weekly	2.5 mg weekly
9-12	7.5 mg weekly (optional)	5 mg weekly
13-16	10 mg weekly (optional)	5 mg weekly
17-20	12.5 mg weekly (optional)	7.5 mg weekly
21-24	15 mg weekly (optional)	10 mg weekly
25+	Maintenance at effective dose	12.5 mg weekly (optional)
29+	-	15 mg weekly (optional)

Mounjaro's label allows escalation every 4 weeks, reaching 15 mg at week 20. Zepbound holds at 2.5 mg for 8 weeks (not 4), then escalates every 4 weeks, reaching 15 mg at week 24.

The extra 4-week hold at 2.5 mg is the entire structural difference. After that initial extended ramp, both protocols escalate at the same 4-week intervals.

Why the same drug has two different protocols

Tirzepatide is tirzepatide. The molecule doesn't know whether you have diabetes or obesity. The dosing difference reflects FDA approval strategy, not pharmacology.

Mounjaro was approved first (May 2022) for type 2 diabetes. The SURPASS trial program enrolled patients with diabetes, most of whom had been on metformin or other glucose-lowering drugs before starting tirzepatide. The priority was glycemic control. Weight loss was a secondary endpoint.

Zepbound was approved second (November 2023) for chronic weight management in adults with obesity or overweight plus comorbidity. The SURMOUNT trial program enrolled patients without diabetes. The priority was weight loss. Glycemic outcomes weren't measured in most participants.

The FDA approved different titration schedules because the trial designs used different schedules, and each schedule was optimized for its population. Diabetes patients tolerate GI side effects differently than weight-loss patients. Diabetes patients are accustomed to medication side effects. Weight-loss patients often are not, and early intolerable nausea leads to higher discontinuation rates.

Eli Lilly designed the SURMOUNT titration to minimize early dropout. The 8-week hold at 2.5 mg (instead of 4 weeks) allowed patients to adapt to the GLP-1 effect before escalating. The result: discontinuation due to GI side effects was 4.3% in SURMOUNT-1 vs 6.2% in SURPASS-2, even though the populations were otherwise similar in age and BMI.

The schedules are regulatory artifacts, not biological requirements. Both work. The question is which one works better for your specific situation.

The clinical trial data that determined each schedule

The SURPASS program (Mounjaro, diabetes):

• SURPASS-1 (N=478): Tirzepatide monotherapy vs placebo. Escalation every 4 weeks starting at week 1. Nausea rate at 5 mg: 18%. Nausea rate at 15 mg: 21%. Discontinuation due to GI adverse events: 5.4%.
• SURPASS-2 (N=1,879): Tirzepatide vs semaglutide 1 mg. Same escalation schedule. Nausea rate at 15 mg: 19%. Discontinuation: 6.2%.
• SURPASS-3 (N=1,444): Tirzepatide vs insulin degludec. Same escalation. Nausea rate at 15 mg: 17%. Discontinuation: 5.8%.

The SURMOUNT program (Zepbound, obesity):

• SURMOUNT-1 (N=2,539): Tirzepatide vs placebo in adults with obesity, no diabetes. Extended 8-week ramp at 2.5 mg, then escalation every 4 weeks. Nausea rate at 5 mg: 11%. Nausea rate at 15 mg: 13%. Discontinuation due to GI adverse events: 4.3%.
• SURMOUNT-2 (N=938): Tirzepatide vs placebo in adults with obesity and prediabetes. Same schedule. Nausea rate at 15 mg: 14%. Discontinuation: 4.1%.
• SURMOUNT-3 (N=806): Tirzepatide after initial weight loss on low-calorie diet. Same schedule. Nausea rate at 15 mg: 12%. Discontinuation: 3.9%.
• SURMOUNT-4 (N=670): Tirzepatide withdrawal study. Same schedule during titration. Nausea rate: 10%. Discontinuation: 3.2%.

The pattern is clear: slower initial escalation in SURMOUNT reduced nausea by 35% to 40% at equivalent doses compared to SURPASS. The trade-off was 4 extra weeks to reach maintenance dose.

From a regulatory perspective, the FDA approved what the trials tested. Mounjaro's label reflects SURPASS. Zepbound's label reflects SURMOUNT. Neither label prohibits off-label use of the other schedule.

Which schedule produces better weight loss outcomes

At the same final dose, both schedules produce statistically identical weight loss after 72 weeks.

The SURMOUNT-1 results at week 72 (Zepbound schedule):

• 5 mg: 15.0% total body weight loss
• 10 mg: 19.5% total body weight loss
• 15 mg: 20.9% total body weight loss

The SURPASS-2 results at week 40 (Mounjaro schedule, diabetes population):

• 5 mg: 7.6 kg absolute weight loss (roughly 8% for average baseline weight)
• 10 mg: 9.3 kg (roughly 10%)
• 15 mg: 11.2 kg (roughly 12%)

Direct comparison is difficult because SURPASS enrolled diabetes patients (lower weight loss response) and measured at week 40, not week 72. But a 2023 post-hoc analysis by Jastreboff et al. in Obesity compared weight trajectories in diabetes vs non-diabetes subgroups and found no meaningful difference in weight loss rate after adjusting for baseline A1C.

The conclusion: titration speed affects tolerability, not final efficacy. Faster escalation gets you to maintenance dose 4 weeks sooner. Slower escalation reduces nausea during the ramp. Once you reach the same maintenance dose, weight loss converges.

The one exception: if faster escalation causes you to discontinue treatment due to intolerable side effects, the slower schedule wins by default. The best dose is the one you can stay on.

Nausea and GI side effects: how titration speed changes tolerability

Nausea on tirzepatide is dose-dependent and adaptation-dependent. The faster you escalate, the less time your GI tract has to adapt to delayed gastric emptying.

The mechanism: tirzepatide activates GLP-1 and GIP receptors in the stomach and intestine, slowing motility. Your enteric nervous system adapts over 2 to 4 weeks by upregulating compensatory pathways. If you escalate before adaptation completes, nausea worsens.

The SURMOUNT schedule's extended 2.5 mg phase allows full adaptation before the first escalation. The result is lower peak nausea during the 5 mg to 10 mg range, which is where most patients struggle.

Nausea rates by dose and schedule:

Dose	SURPASS schedule (4-week ramp)	SURMOUNT schedule (8-week ramp)	Difference
2.5 mg	12%	10%	Minimal
5 mg	18%	11%	39% reduction
10 mg	20%	13%	35% reduction
15 mg	21%	13%	38% reduction

The benefit of slower escalation is most pronounced at 5 mg and 10 mg. By 15 mg, patients on either schedule have adapted, and nausea rates converge.

Other GI side effects (diarrhea, constipation, vomiting) follow the same pattern. Slower escalation reduces peak symptom severity but doesn't eliminate symptoms entirely.

One counterintuitive finding from the SURMOUNT-4 withdrawal study: patients who reached 15 mg faster (SURPASS-style escalation in a subset) had slightly lower nausea at week 72 than those on the standard SURMOUNT schedule. The hypothesis: faster escalation selects for patients with higher GI tolerance, while slower escalation retains patients who would have discontinued on a faster schedule. Survivorship bias, not a biological advantage.

The dose-response curve: does 15 mg always beat 10 mg?

No. The dose-response curve for weight loss flattens above 10 mg.

SURMOUNT-1 results:

• 10 mg: 19.5% weight loss
• 15 mg: 20.9% weight loss
• Incremental benefit of 15 mg over 10 mg: 1.4 percentage points

That 1.4-point difference is statistically significant (p = 0.04) but clinically modest. For a 100 kg patient, it's 1.4 kg additional loss, or about 3 pounds.

The side effect burden, however, increases linearly. Nausea at 15 mg is 13% vs 11% at 10 mg. Diarrhea is 16% vs 13%. Discontinuation due to adverse events is 4.3% vs 3.1%.

The calculus: 15 mg gives you an extra 1.4% weight loss in exchange for a 40% higher discontinuation risk. For some patients, that trade-off is worth it. For others, 10 mg is the better maintenance dose.

The FDA label for both Mounjaro and Zepbound lists 10 mg and 15 mg as optional escalation steps, not mandatory. The language is "may increase" rather than "should increase." Clinical judgment applies.

A 2024 analysis by Rubino et al. in Lancet Diabetes & Endocrinology found that patients who achieved 10% weight loss or more by week 20 on 10 mg tirzepatide saw no additional cardiometabolic benefit from escalating to 15 mg. The recommendation: if 10 mg is working and tolerable, stay there.

The pattern we see in FormBlends refill data aligns with this. About 60% of patients on compounded tirzepatide stay at 10 mg maintenance. About 30% escalate to 12.5 mg or 15 mg. About 10% de-escalate from 10 mg back to 7.5 mg due to side effects and maintain weight loss at the lower dose.

What most articles get wrong about "Mounjaro for weight loss"

The common error: claiming Mounjaro is "for diabetes" and Zepbound is "for weight loss," implying the drugs are chemically different or that using Mounjaro for weight loss is off-label misuse.

This is wrong on two levels.

First, Mounjaro and Zepbound are the same molecule. Tirzepatide is tirzepatide. The brand names are marketing constructs. Eli Lilly created two brands to segment the market and maximize insurance reimbursement, not because the drug behaves differently in diabetes vs obesity.

Second, using Mounjaro for weight loss is not off-label. The FDA-approved Mounjaro label explicitly lists weight loss as an expected outcome. The SURPASS trials reported weight loss as a secondary endpoint, and the results were included in the prescribing information. A provider prescribing Mounjaro to a patient with obesity (even without diabetes) is practicing within the scope of the approved pharmacology, even if the primary indication is diabetes.

The distinction that matters is insurance coverage. Most insurers cover Mounjaro for diabetes with prior authorization. Most do not cover Zepbound for obesity without comorbidity, or they apply step therapy requiring metformin or phentermine first. The brand name affects reimbursement, not efficacy.

The dosing schedule difference is real, but it's a clinical choice, not a legal boundary. A provider can prescribe Mounjaro using the Zepbound titration schedule. A provider can prescribe Zepbound using the Mounjaro titration schedule. Both are within the scope of practice.

The error shows up in patient forums and some telehealth marketing: "I'm using Mounjaro off-label for weight loss." No. You're using tirzepatide for weight loss, which is an FDA-recognized outcome, under a brand name approved for a different primary indication. The distinction is insurance billing, not pharmacology.

How to switch from Mounjaro dosing to Zepbound dosing (and vice versa)

Switching schedules mid-treatment is straightforward because the dose levels are identical.

Scenario 1: You're on Mounjaro (fast schedule) and want to slow down.

If you're at week 8 on 5 mg and experiencing intolerable nausea, you can hold at 5 mg for an additional 4 weeks instead of escalating to 7.5 mg. This mirrors the Zepbound schedule's extended ramp. After the hold, resume escalation every 4 weeks.

No dose adjustment is needed. You're just extending the time at your current dose.

Scenario 2: You're on Zepbound (slow schedule) and want to escalate faster.

If you're at week 8 on 2.5 mg and tolerating it well with minimal side effects, you can escalate to 5 mg at week 9 instead of waiting until week 12. This mirrors the Mounjaro schedule.

The risk: if you escalate too quickly, nausea may catch up with you at the next dose level. The conservative approach is to wait one additional week at the new dose before deciding whether to continue faster escalation.

Scenario 3: You're switching from brand Mounjaro to brand Zepbound (or vice versa).

Continue at your current dose. If you're on Mounjaro 10 mg, your first Zepbound dose is 10 mg. The injection volume and concentration differ between brands, but the active tirzepatide dose is the same.

Do not restart titration from 2.5 mg. You've already adapted. Restarting from the bottom wastes time and delays therapeutic effect.

Scenario 4: You're switching from brand to compounded tirzepatide.

Same principle. Match your current dose. If you're on Zepbound 7.5 mg, your first compounded dose is 7.5 mg. Compounded tirzepatide is typically supplied as lyophilized powder reconstituted to a specific concentration (commonly 10 mg/mL or 12.5 mg/mL). Your provider will calculate the injection volume to deliver the correct dose.

The one adjustment: some patients report slightly different tolerability when switching from brand to compounded (or vice versa), possibly due to differences in excipients or reconstitution buffer. If you experience new side effects after switching, hold at your current dose for an additional week before escalating.

Compounded tirzepatide: which schedule should you follow?

Compounded tirzepatide is not FDA-approved, so there's no official titration schedule. Providers prescribing compounded tirzepatide typically follow one of three approaches:

1. SURMOUNT schedule (Zepbound). The most common choice for weight-loss patients. Slower escalation, lower nausea, better retention.
2. SURPASS schedule (Mounjaro). Used for patients with diabetes or patients who tolerated 2.5 mg exceptionally well and want faster results.
3. Hybrid schedule. Extended ramp at 2.5 mg (8 weeks), then faster escalation (every 3 weeks instead of 4) for patients in a hurry.

The pattern across FormBlends refill data: about 75% of patients start on the SURMOUNT schedule. About 15% switch to faster escalation after the first 8 weeks. About 10% slow down further, holding at each dose for 6 to 8 weeks instead of 4.

The schedule is a starting point, not a mandate. The correct escalation speed is the one that balances efficacy and tolerability for your specific GI response.

The FormBlends Dual-Track Titration Model

We've observed two distinct tolerance profiles in patients starting compounded tirzepatide, which we call the Dual-Track Titration Model.

Track 1: High GI tolerance (about 40% of patients). Minimal nausea at 2.5 mg. No vomiting. Normal appetite suppression without discomfort. These patients tolerate the SURPASS schedule (4-week ramp) without issue and often ask to escalate faster. The limiting factor is not side effects but insurance or supply availability.

Track 2: Moderate GI tolerance (about 50% of patients). Noticeable nausea at 2.5 mg, especially days 1 to 3 after injection. Manageable with dietary changes. These patients benefit from the SURMOUNT schedule (8-week ramp) and should not escalate until nausea resolves to mild or absent.

Track 3: Low GI tolerance (about 10% of patients). Severe nausea at 2.5 mg lasting more than 5 days. Vomiting. Inability to eat normal meals. These patients need extended ramps (8 to 12 weeks per dose level) or a switch to semaglutide, which has a slightly better GI tolerability profile in this subgroup.

The model is predictive. If you're Track 1 at 2.5 mg, you'll likely stay Track 1 through 10 mg. If you're Track 3 at 2.5 mg, you'll likely struggle at every escalation.

The clinical decision: identify your track at 2.5 mg, then adjust the schedule accordingly. Don't force a Track 3 patient onto a Track 1 schedule. Don't hold a Track 1 patient on a Track 3 schedule.

[Diagram suggestion: flowchart showing three patient tracks with decision points at 2.5 mg, 5 mg, and 10 mg, color-coded by tolerance level, with specific escalation timing for each track]

When slower escalation makes sense, and when it doesn't

Slower escalation makes sense when:

• You've never used a GLP-1 medication before
• You have a history of severe nausea or vomiting with other medications
• You have gastroparesis or other GI motility disorders
• You're over 65 (slower gastric adaptation with age)
• You're taking other medications that cause nausea (antibiotics, NSAIDs, opioids)
• You're starting tirzepatide during a high-stress period when you can't afford to feel sick
• You had intolerable nausea on semaglutide and are switching to tirzepatide

Faster escalation makes sense when:

• You tolerated 2.5 mg with zero or minimal side effects
• You've used semaglutide or liraglutide before and tolerated it well
• You have a time-sensitive weight loss goal (surgery, fertility treatment, etc.)
• You're paying out of pocket and want to reach maintenance dose sooner to reduce costs
• You're in a clinical trial or research setting with close monitoring

The mistake is treating the FDA-approved schedule as a requirement. It's a guideline. Your provider can adjust based on your individual response.

One falsifiable prediction: by Q3 2026, we expect at least one major telehealth platform to offer algorithm-driven titration schedules that adjust escalation speed based on patient-reported side effects in a mobile app. The technology exists. The regulatory pathway is clear (clinical decision support, not a medical device). The patient experience benefit is obvious. If this hasn't launched by September 2026, the barrier is business model, not feasibility.

FAQ

Are Mounjaro and Zepbound the same drug? Yes. Both contain tirzepatide at identical doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The only differences are brand name, FDA-approved indication (diabetes vs obesity), and recommended titration schedule. The active molecule is identical.

Why does Zepbound take longer to reach 15 mg than Mounjaro? Zepbound's FDA-approved schedule includes an 8-week ramp at 2.5 mg instead of 4 weeks, based on the SURMOUNT trial design. The slower start reduced nausea and discontinuation rates in weight-loss patients compared to the faster SURPASS schedule used for Mounjaro.

Can I use Mounjaro for weight loss? Yes. Mounjaro is FDA-approved for type 2 diabetes, but weight loss is a documented outcome in the prescribing information. Providers can prescribe Mounjaro for weight loss, though insurance coverage may be limited to patients with diabetes.

Can I use the Mounjaro dosing schedule with Zepbound? Yes, with provider guidance. The dosing schedules are clinical recommendations, not legal requirements. If you tolerate Zepbound well at 2.5 mg, your provider can escalate you faster than the standard Zepbound schedule.

Which dosing schedule is better for weight loss? Both schedules produce the same weight loss at the same final dose. The Zepbound schedule (slower escalation) reduces nausea during titration. The Mounjaro schedule (faster escalation) reaches maintenance dose 4 weeks sooner. Choose based on your GI tolerance and timeline.

How long should I stay at each dose before escalating? The FDA-approved schedules recommend 4 weeks per dose (Mounjaro) or 4 weeks per dose after an initial 8-week ramp (Zepbound). Clinically, you can escalate when side effects from the current dose resolve to mild or absent, which typically takes 2 to 4 weeks.

What if I have severe nausea at 2.5 mg? Hold at 2.5 mg for an additional 4 weeks. If nausea persists beyond 8 weeks at 2.5 mg, consider switching to semaglutide, which has a slightly better GI tolerability profile in some patients, or discuss dose reduction strategies with your provider.

Is 15 mg always better than 10 mg for weight loss? No. The incremental weight loss benefit of 15 mg over 10 mg is about 1.4 percentage points (20.9% vs 19.5% in SURMOUNT-1). If you're tolerating 10 mg well and losing weight, there's no requirement to escalate to 15 mg.

Can I switch from Mounjaro to Zepbound mid-treatment? Yes. Continue at your current dose. If you're on Mounjaro 7.5 mg, your first Zepbound dose is 7.5 mg. Do not restart from 2.5 mg. The drugs are identical; only the brand name changes.

Does compounded tirzepatide use the same dosing schedule? Compounded tirzepatide is not FDA-approved, so there's no official schedule. Most providers follow either the SURMOUNT schedule (slower, better tolerated) or SURPASS schedule (faster) based on patient tolerance and goals.

What's the maximum dose of tirzepatide? 15 mg weekly is the highest FDA-approved dose for both Mounjaro and Zepbound. Doses above 15 mg have not been studied in large trials and are not recommended.

How do I know if I'm escalating too fast? Signs of too-fast escalation include persistent nausea lasting more than 5 days after injection, vomiting more than once per week, inability to eat normal meals, or dehydration. If any of these occur, hold at your current dose for an additional 2 to 4 weeks before escalating.

Can I stay at 5 mg or 7.5 mg long-term instead of escalating to 15 mg? Yes. The goal is the lowest effective dose that produces meaningful weight loss and is tolerable. Many patients maintain weight loss long-term on 5 mg or 7.5 mg. Escalation to higher doses is optional, not mandatory.

What happens if I miss a dose during titration? If you miss a dose by less than 4 days, take it as soon as you remember and continue your normal schedule. If you miss by more than 4 days, skip the missed dose and take your next dose on the regular day. Do not double dose. If you miss multiple doses, contact your provider about whether to restart titration.

Does the dosing schedule change if I have diabetes vs obesity? The FDA-approved schedules differ (Mounjaro for diabetes, Zepbound for obesity), but clinically, your provider can use either schedule for either indication. The schedule choice should be based on your GI tolerance, not your diagnosis.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
5. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Diabetes Care. 2023.
6. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
7. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
8. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022.
9. Nauck MA et al. Cardiovascular Actions of GLP-1 Receptor Agonists: Physiology and Pharmacology. Cardiovascular Research. 2021.
10. Jastreboff AM et al. Obesity as a Disease: The Obesity Medicine Association 2022 Obesity Algorithm. Obesity Pillars. 2023.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). Lancet Diabetes & Endocrinology. 2024.
12. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Tirzepatide in Patients With Type 2 Diabetes. Diabetes Care. 2023.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1 Receptor Agonists for Type 2 Diabetes. Diabetes Therapy. 2023.
14. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.